CHINA ISOTOPE & RADIATION CORPORATION China Isotope & Radiation Corporation Share Price
Equities
1763
CNE1000031F4
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.3 HKD | -1.34% |
|
-6.36% | -22.90% |
| Sales 2022 | 6.15B 849M 6.63B 70.83B | Sales 2023 | 6.63B 917M 7.16B 76.47B | Capitalization | 3.88B 537M 4.19B 44.77B |
|---|---|---|---|---|---|
| Net income 2022 | 392M 54.16M 423M 4.52B | Net income 2023 | 371M 51.26M 400M 4.28B | EV / Sales 2022 | 0.28 x |
| Net cash position 2022 | 2.06B 285M 2.23B 23.78B | Net cash position 2023 | 1.24B 171M 1.34B 14.28B | EV / Sales 2023 | 0.4 x |
| P/E ratio 2022 |
9.65
x | P/E ratio 2023 |
10.5
x | Employees | 3,105 |
| Yield 2022 |
3.73% | Yield 2023 |
2.58% | Free-Float | 91.21% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.34% | ||
| 1 week | -6.36% | ||
| Current month | -3.56% | ||
| 1 month | -6.36% | ||
| 3 months | -12.41% | ||
| 6 months | -16.12% | ||
| Current year | -22.90% |
1 week
10.28
10.90
1 month
10.2811.48
Current year
9.0313.26
1 year
9.0316.50
3 years
9.0332.10
5 years
9.0335.40
10 years
9.0335.40
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Min Fan
BRD | Director/Board Member | 54 | 01/16/01 |
Hong Chao Xu
BRD | Director/Board Member | 53 | 29/22/29 |
You Quan Gui
AUD | Comptroller/Controller/Auditor | 50 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiu Hong Liu
BRD | Director/Board Member | 57 | 30/20/30 |
Zhong Lin Liu
BRD | Director/Board Member | 55 | 22/17/22 |
Shou Lei Chen
BRD | Director/Board Member | 58 | 22/17/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/24/12 | 10.3 | -1.34% | 91 400 |
| 11/24/11 | 10.44 | -2.43% | 90,200 |
| 07/24/07 | 10.7 | -1.11% | 29,800 |
| 06/24/06 | 10.82 | -0.92% | 83,600 |
| 05/24/05 | 10.92 | -0.73% | 59,011 |
Delayed Quote Hong Kong S.E., June 12, 2024 at 01:38 pm IST
More quotes
China Isotope & Radiation Corporation is a China-based company mainly engaged in research, development, manufacturing and sales of radiopharmaceuticals and radioactive source products. The Company operates mainly through five segments. The Pharmaceuticals segment is mainly engaged in the manufacture and sales of various radiopharmaceuticals for imaging diagnosis and treatment, urea breath test kits and testers, as well as in vitro diagnostic reagents and kits. The Radioactive Source Product segment is mainly engaged in the production and sales of various radioactive source products, and provides related technical services. The Irradiation segment mainly provides irradiation sterilization services and others. The Radiotherapy Equipment and Related Services segment is mainly engaged in the research and development of radiotherapy equipment. The Independent Medical Laboratory Services and Other Business segment mainly provides independent medical laboratory services.
Calendar
30/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.90% | 428M | |
| -2.58% | 8.11B | |
| +7.73% | 5.67B | |
| +31.27% | 5.62B | |
| -15.77% | 3.89B | |
| +12.42% | 2.68B | |
| -61.15% | 2.58B | |
| -5.50% | 2.26B | |
| +25.05% | 2.03B | |
| -9.25% | 1.82B |
- Stock Market
- Equities
- 1763 Stock
